Hydroxyurea and EPO in Sickle Cell Disease
- Conditions
- Anemia, Sickle CellSickle Cell Disease
- Interventions
- Registration Number
- NCT05451940
- Lead Sponsor
- Julia Xu
- Brief Summary
The proposed study is a Phase 1/2 multi-center study evaluating the safety and efficacy of erythropoietin (EPO) in combination with hydroxyurea in the treatment of chronic anemia in patients with sickle cell disease (SCD).
- Detailed Description
Sickle cell disease (SCD) is a devastating inherited hemoglobin disorder characterized by recurrent episodes of pain and chronic hemolytic anemia. Chronic anemia contributes to multi-organ damage and decreased life expectancy in SCD. However, there are limited treatment options for anemia in SCD. Erythropoietin (EPO) is the standard of care for treatment of anemia related to chronic kidney disease (CKD) and is also used ad hoc in patients with SCD. However, there is limited data on the safety and efficacy of EPO in patients with SCD, especially in combination with hydroxyurea. Therefore, this study aims to treat patients on stable hydroxyurea therapy with subcutaneous EPO, with the goal of assessing the safety of EPO therapy and its effect on chronic anemia in SCD.
(Note: Outcome measure changes were in place prior to study initiation.)
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 15
- Aged ≥ 18 years
- Confirmed diagnosis of SCD (HbSS or HbS/β0-thalassemia genotypes)
- Screening Hb ≤ 9.0 g/dL
- Screening transferrin saturation ≥ 20% and ferritin ≥ 50 ng/mL
- Must be on stable-dose hydroxyurea treatment (i.e., no changes in dose within 60 days prior to start of study drug) and plan to continue taking hydroxyurea at the same dose and schedule during the study
- If receiving L-glutamine or crizanlizumab, must have been receiving the drug at a stable dose for at least 60 days prior to screening and plan to continue taking the drug at the same dose and schedule during the study
- Participating in a chronic transfusion program (pre-planned series of transfusions for prophylactic purposes) and/or planning on undergoing an exchange transfusion during the duration of the study; episodic transfusion in response to worsened anemia or VOC is permitted, but participant should not have received a blood transfusion within 60 days of start of study drug
- Received voxelotor or EPO within 30 days of start of study drug
- Untreated iron deficiency, or had initiation or change in dose of supplemental iron within 30 days of start of study drug
- Ongoing acute illness, infection, or VOC within 2 weeks of start of study drug
- Arterial or venous thrombosis within 180 days of start of study drug
- Grade 3 hypertension (defined as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg; medical intervention indicated; more than one drug or more intensive therapy than previously used indicated) on two consecutive measurements
- Unstable angina, uncontrolled seizure disorder, or active malignancy
- End-stage renal disease requiring hemodialysis
- Current pregnancy or breastfeeding
- Received active treatment on another investigational trial within 30 days (or 5 half-lives of that agent, whichever is greater) prior to start of study drug or plans to participate in another investigational drug trial
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Erythropoietin Hydroxyurea Subjects on a stable dose of hydroxyurea will be treated with increasing doses of subcutaneous erythropoietin (EPO) as tolerated for an initial 12 weeks, during which the main safety and efficacy endpoints (including the primary endpoint of hemoglobin response) will be assessed. Subjects may continue on treatment for an additional 12 weeks as clinically indicated, with assessment of additional endpoints at the end of the 24-week study period. Erythropoietin Epoetin Alfa Subjects on a stable dose of hydroxyurea will be treated with increasing doses of subcutaneous erythropoietin (EPO) as tolerated for an initial 12 weeks, during which the main safety and efficacy endpoints (including the primary endpoint of hemoglobin response) will be assessed. Subjects may continue on treatment for an additional 12 weeks as clinically indicated, with assessment of additional endpoints at the end of the 24-week study period.
- Primary Outcome Measures
Name Time Method Change in hemoglobin (Hb) level Baseline to 12 weeks Hb response, defined as a Hb increase of ≥ 1.0 g/dL at 12 weeks compared to baseline
- Secondary Outcome Measures
Name Time Method Change in frequency of blood transfusions Baseline to 12 weeks Annualized number of units of simple red blood cell transfusions received in the 12 months before treatment initiation compared to during active treatment.
Trial Locations
- Locations (2)
UPMC
🇺🇸Pittsburgh, Pennsylvania, United States
Lagos University Teaching Hospital
🇳🇬Lagos, Nigeria